Literature DB >> 22038540

Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri.

Pepijn van den Munckhof1, Imke Christiaans, Susan B Kenter, Frank Baas, Theo J M Hulsebos.   

Abstract

Schwannomatosis is a rare hereditary cancer syndrome in which patients develop multiple non-vestibular schwannomas. The chromatin remodelling gene SMARCB1 (also known as INI1, hSNF5, and BAF47) has been identified as a schwannomatosis predisposing gene, being involved in a subset of sporadic and familial cases. Recent studies have shown that SMARCB1 may also be involved in the development of multiple meningiomas. Previously, we demonstrated that the SMARCB1 exon 2 missense mutation c.143 C > T segregates with the presence of meningiomas in five members of a large family with multiple meningiomas and schwannomas. We extended our genetic analyses by screening 44 additional at-risk family members and identified 13 new carriers. Eleven of these were subjected to magnetic resonance imaging (MRI) of brain and spine. In addition, we analyzed four meningiomas and two schwannomas from family members for the presence of schwannomatosis-specific changes. We found in each tumor retention of the SMARCB1 exon 2 mutation, acquisition of an independent neurofibromatosis type 2 (NF2) gene mutation, and loss of heterozygosity at SMARCB1 and NF2 by loss of the wild-type copy of both genes. The MRI scans revealed one or more falx meningiomas in seven of 11 (64%) newly identified SMARCB1 mutation carriers. We conclude that the SMARCB1 exon 2 missense mutation in this family predisposes to the development of meningiomas as well as schwannomas, occurring via the same genetic pathways, and that this mutation preferentially induces cranial meningiomas located at the falx cerebri.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22038540     DOI: 10.1007/s10048-011-0300-y

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  14 in total

1.  Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas.

Authors:  K D Hadfield; M J Smith; J E Urquhart; A J Wallace; N L Bowers; A T King; S A Rutherford; D Trump; W G Newman; D G Evans
Journal:  Oncogene       Date:  2010-08-23       Impact factor: 9.867

2.  SMARCB1 mutations are not a common cause of multiple meningiomas.

Authors:  K D Hadfield; M J Smith; D Trump; W G Newman; D G Evans
Journal:  J Med Genet       Date:  2010-05-14       Impact factor: 6.318

3.  SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis.

Authors:  Guillaume Rousseau; Tetsuro Noguchi; Violaine Bourdon; Hagay Sobol; Sylviane Olschwang
Journal:  BMC Neurol       Date:  2011-01-24       Impact factor: 2.474

4.  Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas.

Authors:  I Christiaans; S B Kenter; H C Brink; T A M van Os; F Baas; P van den Munckhof; A M J Kidd; T J M Hulsebos
Journal:  J Med Genet       Date:  2010-10-07       Impact factor: 6.318

5.  Anatomic location is a risk factor for atypical and malignant meningiomas.

Authors:  Ari J Kane; Michael E Sughrue; Martin J Rutkowski; Gopal Shangari; Shanna Fang; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

6.  Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis.

Authors:  K D Hadfield; W G Newman; N L Bowers; A Wallace; C Bolger; A Colley; E McCann; D Trump; T Prescott; D G R Evans
Journal:  J Med Genet       Date:  2008-02-19       Impact factor: 6.318

7.  Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.

Authors:  M H Ruttledge; J Sarrazin; S Rangaratnam; C M Phelan; E Twist; P Merel; O Delattre; G Thomas; M Nordenskjöld; V P Collins
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

8.  Falx meningiomas: surgical results and lessons learned from 68 cases.

Authors:  Sang-Bong Chung; Chae-Yong Kim; Chul-Kee Park; Dong Gyu Kim; Hee-Won Jung
Journal:  J Korean Neurosurg Soc       Date:  2007-10-20

9.  Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation.

Authors:  Costanza Bacci; Roberta Sestini; Aldesia Provenzano; Irene Paganini; Irene Mancini; Berardino Porfirio; Rossella Vivarelli; Maurizio Genuardi; Laura Papi
Journal:  Neurogenetics       Date:  2009-07-07       Impact factor: 2.660

10.  Analysis of mutations in the SCH gene in schwannomas.

Authors:  E K Bijlsma; P Merel; D A Bosch; A Westerveld; O Delattre; G Thomas; T J Hulsebos
Journal:  Genes Chromosomes Cancer       Date:  1994-09       Impact factor: 5.006

View more
  35 in total

Review 1.  Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis.

Authors:  Till Holsten; Susanne Bens; Florian Oyen; Karolina Nemes; Martin Hasselblatt; Uwe Kordes; Reiner Siebert; Michael C Frühwald; Reinhard Schneppenheim; Ulrich Schüller
Journal:  Eur J Hum Genet       Date:  2018-04-30       Impact factor: 4.246

2.  Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.

Authors:  Scott R Plotkin; Jaishri O Blakeley; D Gareth Evans; C Oliver Hanemann; Theo J M Hulsebos; Kim Hunter-Schaedle; Ganjam V Kalpana; Bruce Korf; Ludwine Messiaen; Laura Papi; Nancy Ratner; Larry S Sherman; Miriam J Smith; Anat O Stemmer-Rachamimov; Jeremie Vitte; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2013-02-07       Impact factor: 2.802

Review 3.  SWI/SNF chromatin remodeling complexes and cancer.

Authors:  Jaclyn A Biegel; Tracy M Busse; Bernard E Weissman
Journal:  Am J Med Genet C Semin Med Genet       Date:  2014-08-28       Impact factor: 3.908

4.  Genomic analysis of synchronous intracranial meningiomas with different histological grades.

Authors:  Tamrin Chowdhury; Yongjin Yoo; Youngbeom Seo; Yun-Sik Dho; Sojin Kim; Anna Choi; Murim Choi; Sung-Hye Park; Chul-Kee Park; Sang Hyung Lee; Ji Yeoun Lee
Journal:  J Neurooncol       Date:  2018-02-08       Impact factor: 4.130

5.  SWI/SNF chromatin remodeling complex alterations in meningioma.

Authors:  Corey M Gill; Joshua Loewenstern; John W Rutland; Hanane Arib; Margaret Pain; Melissa Umphlett; Yayoi Kinoshita; Russell B McBride; Joshua Bederson; Michael Donovan; Robert Sebra; Mary Fowkes; Raj K Shrivastava
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-14       Impact factor: 4.553

6.  Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis.

Authors:  Miriam J Smith; Andrew J Wallace; Naomi L Bowers; Cecilie F Rustad; C Geoff Woods; Guy D Leschziner; Rosalie E Ferner; D Gareth R Evans
Journal:  Neurogenetics       Date:  2012-03-22       Impact factor: 2.660

7.  Comment on the article "Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri" by van den Munckhof et al.

Authors:  Trine E Prescott; Miriam J Smith; D Gareth Evans
Journal:  Neurogenetics       Date:  2011-12-28       Impact factor: 2.660

8.  DNA methylation analysis for the treatment of meningiomas.

Authors:  Julian L Gendreau; Kevin K H Chow; Eric S Sussman; Aditya Iyer; Arjun V Pendharkar; Allen L Ho
Journal:  J Vis Surg       Date:  2017-12-05

9.  Genetic profiling by single-nucleotide polymorphism-based array analysis defines three distinct subtypes of orbital meningioma.

Authors:  Cheng-Ying Ho; Stacy Mosier; Janice Safneck; Diva R Salomao; Neil R Miller; Charles G Eberhart; Christopher D Gocke; Denise A S Batista; Fausto J Rodriguez
Journal:  Brain Pathol       Date:  2014-05-21       Impact factor: 6.508

Review 10.  Meningiomas from a developmental perspective: exploring the crossroads between meningeal embryology and tumorigenesis.

Authors:  Julien Boetto; Matthieu Peyre; Michel Kalamarides
Journal:  Acta Neurochir (Wien)       Date:  2020-11-20       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.